Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous gp96 Immunotherapy for Glioblastoma
NCT03650257Phase 2Unknown
- Sponsor
- Cure & Sure Biotech
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gp96 in glioblastoma (GBM) (2 arms), sponsored by Cure & Sure Biotech. Primary endpoint: 1-year survival rate. Status: unknown.
02
Drugs
gp96
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03650257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650257.